# The Neurobiological Effect of 5-HT2AR Modulation

> **NCT03289949** · PHASE1 · RECRUITING · sponsor: **Gitte Moos Knudsen** · enrollment: 200 (estimated)

## Conditions studied

- Basic Science

## Interventions

- **DRUG:** Psilocybine
- **DRUG:** Ketanserin

## Key facts

- **NCT ID:** NCT03289949
- **Lead sponsor:** Gitte Moos Knudsen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-03
- **Primary completion:** 2030-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289949, "The Neurobiological Effect of 5-HT2AR Modulation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03289949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*